REGENXBIO Inc, the clinical-stage biotechnology company that specializes in gene therapy, is providing gene therapy product candidates that have the potential to deliver genes to cells to address genetic defects. These product candidates have the ability to enable cells in the body to produce therapeutic proteins or antibodies which can impact diseases. The gene therapy product candidates are based on the NAV Technology Platform, which is a proprietary adeno-associated virus gene delivery system. Among the company's pipeline product candidates are RGX-314, which has shown promise in treating wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases. RGX-202, which is currently in the Phase I/II clinical trial stage, focuses on treating Duchenne muscular dystrophy. REGENXBIO's other product candidates, which are in various stages of clinical trial, are RGX-121, RGX-111, RGX-181, and RGX-381, with each aimed at treating different types of diseases. The company also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Recently, REGENXBIO announced its collaboration and license agreement with Neurimmune AG, aimed at developing novel gene therapies. Founded in 2008, REGENXBIO Inc. is headquartered in Rockville, Maryland.
Regenxbio's ticker is RGNX
The company's shares trade on the NASDAQ stock exchange
They are based in Rockville, Maryland
There are 51-200 employees working at Regenxbio
It is regenxbio.com
Regenxbio is in the Healthcare sector
Regenxbio is in the Biotechnology industry
The following five companies are Regenxbio's industry peers: